Every one of those 1 sits in a single category, clinical-trial. American Brain Tumor Association is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 5 original sources on average. We currently track 1 Biotech story that mention Glioblastoma, all published on July 25, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Glioblastoma
Every one of those 1 sits in a single category, clinical-trial. American Brain Tumor Association is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 5 original sources on average. We currently track 1 Biotech story that mention Glioblastoma, all published on July 25, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Glioblastoma. Shared-story counts are live from our verified record — not editorial picks.
Annual glioblastoma diagnoses exceed 12,000 with a grim sub-two-year life expectancy, spotlighting a high-priority target for biotech investment and therapeutic innovation. Dr. Annick Desjardins' awareness messaging underscores the rapid proliferation and clinical chaos that keep this disease among oncology’s toughest nuts to crack.